Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771

Documenti analoghi

• Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers
  di: Gray, Michael J., et al.
  Pubblicazione: (2016)
• Targeting of phosphatidylserine by monoclonal antibodies reverses an immunosuppressive checkpoint inducing innate and specific anti-tumor responses
  di: Gong, Jian, et al.
  Pubblicazione: (2013)
• Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
  di: Gong, Jian, et al.
  Pubblicazione: (2014)
• Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma
  di: Freimark, Bruce D., et al.
  Pubblicazione: (2016)
• Targeting phosphatidylserine synergizes with immune checkpoint blockade by inducing de novo tumor specific immunity
  di: Huang, Xianming, et al.
  Pubblicazione: (2015)